[Sapropterin Hydrochloride Tablets and Regiolense Injection were transferred from the Commercial Insurance Innovative Drug Catalog to the National Basic Medical Insurance Catalog] On November 14, reporters learned from the 2026 Innovative Drug High-Quality Development Conference held today that the 2026 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog adjustment results were officially released. Shandong New Era Pharmaceutical's rare disease drug Sapropterin Hydrochloride Tablets and WuXi Junoregi Olense Injection, two CAR-T products that were previously included in the commercially insured innovative drug catalog, have been transferred to the basic medical insurance catalog through medical insurance negotiations this time. Previously, due to the high cost of treatment, CAR-T therapy mainly explored market accessibility through multiple payment channels such as commercial health insurance. This year, some CAR-T products that were previously included in the commercial insurance catalog were further applied for basic medical insurance, becoming an important case in the connection between basic medical insurance and the commercial insurance innovative drug catalog. (Reporters Lu Afeng and Yu Miao)